AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00003262
Drug: Stanford V regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003262
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02651116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL Placebo
Trial: NCT01355614
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00421148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03491033
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
Trial: NCT01284959
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose PO, 3times
Trial: NCT03924544
Drug: Decorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic agent
Trial: NCT02393339
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative administration of placebo syrup
Trial: NCT02546583
Drug: IV Chlorothiazide
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00401843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
Trial: NCT02272946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg Placebo received subcutaneously
Trial: NCT00178971
Drug: adjunctive treatment with buspirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone 15-30 mg qd
Trial: NCT00178971
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00002548
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
Trial: NCT00002548
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks
Trial: NCT02030821
Drug: TXA
RxNorm normalized name: TXA>2<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive TXA will receive this during surgical intervention
Trial: NCT02153489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02405988
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
Trial: NCT04067492
Drug: Voltaren®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablets, 25 mg and 50 mg
Trial: NCT02102243
Drug: DEFINITY® infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
Trial: NCT02102243
Drug: Human Recombinant Regular Insulin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
Trial: NCT02746328
Drug: GTx-024 9 or 18 mg
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
Trial: NCT03837990
Drug: Helicobacter Pylori eradication therapy
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
Trial: NCT02947633
Drug: Continuous sciatic PNB
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief.
Trial: NCT00444925
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily (OD)for 12 weeks
Trial: NCT01406132
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00572598
Drug: 4- [F-18] fluoropaclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
Trial: NCT02911142
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
Trial: NCT02911142
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
Trial: NCT02131662
Drug: BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Trial: NCT02131662
Drug: BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Trial: NCT02131662
Drug: BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Trial: NCT02131662
Drug: BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Trial: NCT02131662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Trial: NCT01402869
Drug: 2% Lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
Trial: NCT00038844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm/m2 by vein daily, 3 days in a row.
Trial: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
Trial: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
Trial: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
Trial: NCT01052883
Drug: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
Trial: NCT02619747
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00295607
Drug: steroids, monoclonal anti-IL2R antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunosuppression
Trial: NCT01521598
Drug: SKL11197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
Trial: NCT01521598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo. Patients will be randomized the placebo.
Trial: NCT01451749
Drug: Shenwu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months.
Trial: NCT01771874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT02264613
Drug: ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALRN-6924 will be administered as an IV infusion
Trial: NCT02524249
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02524249
Drug: Placebo (dextrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03159975
Drug: GX-70 by electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Trial: NCT03159975
Drug: GX-70 by electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Trial: NCT03159975
Drug: GX-70 by electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Trial: NCT00315510
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00921050
Drug: levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
Trial: NCT00921050
Drug: excipient without levothyroxine (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
Trial: NCT04396821
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Trial: NCT01023100
Drug: CP 690,550 oral solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flavored and unflavored prototype CP-690,550 formulations
Trial: NCT02664155
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Of Care
Trial: NCT03160560
Drug: ClōSYS® Unflavored Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Test group will receive ClōSYS® Unflavored Rinse.
Trial: NCT03941483
Drug: ASP1128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT03941483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT03160560
Drug: ClōSYS® Flavored Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Test group will receive ClōSYS® Flavored Rinse.
Trial: NCT03440866
Drug: Administration of drugs concomitantly.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
Trial: NCT01085526
Drug: Alutard phl prat
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00928343
Drug: GLPG0187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
Trial: NCT00928343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching subcutaneous or oral placebo
Trial: NCT03154476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching study drug
Trial: NCT03938831
Drug: Fentanyl-based PCA infusion
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl-based PCA infusion
Trial: NCT03549338
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Trial: NCT00005903
Drug: GDNF & Synchro Med Infusion System
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
Trial: NCT00157963
Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00626535
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Once Daily
Trial: NCT00003873
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00507442
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
Trial: NCT03076281
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03076281
Drug: Metformin +Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03549741
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT00174850
Drug: Gaitril
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01761513
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks
Trial: NCT01761513
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks
Trial: NCT01761513
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks
Trial: NCT01761513
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks
Trial: NCT03581175
Drug: Bowel cleansing regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01903265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Trial: NCT01381367
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline, 0.5ml given subcutaneously
Trial: NCT02173405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of placebo with investigational drug OnabotulinumtoxinA
Trial: NCT02879513
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02879513
Drug: 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 6 weeks
Trial: NCT01774773
Drug: Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Trial: NCT01774773
Drug: Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Trial: NCT01774773
Drug: Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Trial: NCT01126190
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
Trial: NCT04184505
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)
Trial: NCT00829374
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally three times daily
Trial: NCT01046682
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.